Manitou Investment Management Ltd. decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 89,480 shares of the company’s stock after selling 2,974 shares during the period. Johnson & Johnson comprises approximately 3.4% of Manitou Investment Management Ltd.’s holdings, making the stock its 15th largest position. Manitou Investment Management Ltd.’s holdings in Johnson & Johnson were worth $10,854,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in JNJ. Trust Co. of Virginia VA increased its stake in Johnson & Johnson by 8.3% in the first quarter. Trust Co. of Virginia VA now owns 93,345 shares of the company’s stock worth $10,100,000 after buying an additional 7,161 shares in the last quarter. New England Research & Management Inc. increased its stake in Johnson & Johnson by 3.6% in the first quarter. New England Research & Management Inc. now owns 26,130 shares of the company’s stock worth $2,827,000 after buying an additional 900 shares in the last quarter. Indiana Trust & Investment Management CO increased its stake in Johnson & Johnson by 3.1% in the first quarter. Indiana Trust & Investment Management CO now owns 13,259 shares of the company’s stock worth $1,435,000 after buying an additional 395 shares in the last quarter. Stock Yards Bank & Trust Co. increased its stake in Johnson & Johnson by 3.3% in the first quarter. Stock Yards Bank & Trust Co. now owns 81,147 shares of the company’s stock worth $8,780,000 after buying an additional 2,555 shares in the last quarter. Finally, First American Trust FSB increased its stake in Johnson & Johnson by 1,942.4% in the first quarter. First American Trust FSB now owns 50,427 shares of the company’s stock worth $5,456,000 after buying an additional 47,958 shares in the last quarter. Institutional investors and hedge funds own 65.31% of the company’s stock.

Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.25% during trading on Tuesday, reaching $117.95. The company’s stock had a trading volume of 5,187,716 shares. The stock has a 50 day moving average of $120.64 and a 200-day moving average of $116.04. Johnson & Johnson has a 1-year low of $89.90 and a 1-year high of $126.07. The company has a market capitalization of $322.70 billion, a PE ratio of 21.98 and a beta of 0.61.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, July 19th. The company reported $1.74 EPS for the quarter, beating the consensus estimate of $1.68 by $0.06. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. The company had revenue of $18.50 billion for the quarter, compared to analyst estimates of $17.98 billion. On average, analysts expect that Johnson & Johnson will post $6.69 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd were issued a $0.80 dividend. This represents a $3.20 annualized dividend and a yield of 2.71%. The ex-dividend date of this dividend was Friday, August 19th. Johnson & Johnson’s payout ratio is currently 60.15%.

A number of equities research analysts have issued reports on the company. RBC Capital Markets restated an “outperform” rating and set a $133.00 price target (up from $125.00) on shares of Johnson & Johnson in a research note on Wednesday, July 20th. Leerink Swann reiterated an “outperform” rating and set a $140.00 price objective (up from $125.00) on shares of Johnson & Johnson in a research note on Wednesday, July 20th. Royal Bank Of Canada boosted their price objective on Johnson & Johnson from $125.00 to $133.00 and gave the company an “outperform” rating in a research note on Wednesday, July 20th. BMO Capital Markets reiterated an “outperform” rating and set a $132.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, July 20th. Finally, Deutsche Bank AG reiterated a “hold” rating and set a $142.00 price objective (up from $125.00) on shares of Johnson & Johnson in a research note on Thursday, July 21st. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and eleven have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $119.57.

In other Johnson & Johnson news, VP Dominic J. Caruso sold 41,146 shares of the firm’s stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total value of $5,143,661.46. Following the sale, the vice president now directly owns 157,819 shares of the company’s stock, valued at $19,728,953.19. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Ronald A. Kapusta sold 2,935 shares of the firm’s stock in a transaction that occurred on Friday, July 22nd. The shares were sold at an average price of $125.01, for a total value of $366,904.35. Following the completion of the sale, the chief accounting officer now directly owns 28,660 shares in the company, valued at $3,582,786.60. The disclosure for this sale can be found here. 0.11% of the stock is owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.